You are here
November 2017
Features
Perspective
The animus toward placebos arises from the notion that the symptoms they alleviate must belong mostly to psychosomatic illnesses. But lately the mindset that underlies placebo disparagement has been fading. The author talks with experts about placebo research, including implications for provider–patient encounters.
Idarucizumab is the first reversal agent approved for the direct thrombin inhibitor dabigatran. The authors summarize the findings from the clinical trial series and describe case reports, post-marketing data, and ongoing studies.
Approved by the FDA in 2015, idarucizumab is indicated for patients with life-threatening or uncontrolled bleeding, as well as in cases where rapid dabigatran reversal is needed for urgent and emergent procedures. The authors present seven case reports on six patients at a large urban academic medical center.
Departments
Prescription: Washington
Medicare allows add-on payments to hospitals for some new products
New Drugs/Drug News
Approvals, new indications, regulatory activities, and more
Aminolevulinic acid hydrochloride (Gleolan) for the visualization of malignant tissue during surgery; delafloxacin (Baxdela) for certain acute bacterial skin infections; and glecaprevir/pibrentasvir (Mavyret) for chronic HCV infection
Drug Forecast
Lixisenatide (Adlyxin), a once-daily incretin mimetic injection for type-2 diabetes